| Project Number | pCODR 10197 |
|---|---|
| Brand Name | Lonsurf |
| Generic Name | Trifluridine-Tipiracil |
| Tumour Type | Gastrointestinal |
| Indication | Gastric Cancer |
| Funding Request | For the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease |
| Review Status | Pending |
| Pre Noc Submission | Yes |
| NOC Date | |
| Manufacturer | Taiho Pharma Canada, Inc. |
| Submitter | Taiho Pharma Canada, Inc. |
| Submission Date (Target Date) | September 3, 2019 |
| Submission Type | New Indication |
| Prioritization Requested | |
| Stakeholder Input Deadline (target date based on target submission date) ‡ | September 17, 2019 |
| Check-point meeting (target date) | |
| pERC Meeting (target date) | |
| Initial Recommendation Issued (target date) | |
| Feedback Deadline (target date) ‡ | |
| pERC Reconsideration Meeting (target date) | |
| Final Recommendation Issued (target date) | |
| Notification to Implement Issued |
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
